Evidence map›Paper›PMID 39061765›Full record

ArticleBioengineering (Basel, Switzerland)2024

Hip Exoskeleton for Cycling Assistance.

Martin Grimmer, Guoping Zhao

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Martin GrimmerInstitute for Sport Scienceand Department of Electrical Engineering and Information Technology, Technical University of Darmstadt, 64289 Darmstadt, Germany.ORCID 0000-0003-1921-1433
Guoping ZhaoSchool of Mechanical Engineering, Southeast University, Nanjing 211102, China.ORCID 0000-0002-1908-5388

Funding

Deutsche Forschungsgemeinschaft 450821862Southeast University RF1028624035Technical University of Darmstadt 2700967
6 · The paper itself

Abstract

Cycling stands as one of the most widely embraced leisure activities and serves purposes such as exercise, rehabilitation, and commuting. This study aimed to assess the feasibility of assisting three unimpaired participants (age: 34.0 ± 7.9 years, height: 1.86 ± 0.02 m, weight: 75.7 ± 12.7 kg) using the GuroX hip exoskeleton, originally designed for walking assistance, during cycling against a resistance of 1 W/kg. The performance evaluation employed a sweep protocol that manipulated the timing of the exoskeleton's peak extension and flexion torque in addition to human-in-the-loop optimization to enhance these timings based on metabolic cost. Our findings indicate that with a peak assistance torque of approximately 10.3 Nm for extension and flexion, the GuroX substantially reduced the net metabolic cost of cycling by 31.4 ± 8.1% and 26.4 ± 14.1% compared to transparent and without exoskeleton conditions, respectively. This demonstrates the significant potential of a hip exoskeleton developed for walking assistance to profoundly benefit cycling. Additionally, customizing the assistance strategy proves beneficial in maximizing assistance. While we attribute the average motor power to be a major contributor to the reduced cycling effort, participant feedback suggests that user comfort and synchronization between the user and exoskeleton may have played integral roles. Further research should validate our initial findings by employing a larger participant pool in real-world conditions. Incorporating a more diverse set of parameters for the human-in-the-loop optimization could enhance individualized assistance strategies.

Indexed as

assistancecyclingeffortexoskeletonhiphuman-in-the-loop optimizationmetabolic costoptimizationwearable robotics

Identifiers

PMID39061765
PMCPMC11273394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.